These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

496 related articles for article (PubMed ID: 21030459)

  • 1. The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers.
    Sasaki T; Okuda K; Zheng W; Butrynski J; Capelletti M; Wang L; Gray NS; Wilner K; Christensen JG; Demetri G; Shapiro GI; Rodig SJ; Eck MJ; Jänne PA
    Cancer Res; 2010 Dec; 70(24):10038-43. PubMed ID: 21030459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ALK inhibitor resistance in ALK(F1174L)-driven neuroblastoma is associated with AXL activation and induction of EMT.
    Debruyne DN; Bhatnagar N; Sharma B; Luther W; Moore NF; Cheung NK; Gray NS; George RE
    Oncogene; 2016 Jul; 35(28):3681-91. PubMed ID: 26616860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma.
    Bresler SC; Wood AC; Haglund EA; Courtright J; Belcastro LT; Plegaria JS; Cole K; Toporovskaya Y; Zhao H; Carpenter EL; Christensen JG; Maris JM; Lemmon MA; Mossé YP
    Sci Transl Med; 2011 Nov; 3(108):108ra114. PubMed ID: 22072639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK.
    Katayama R; Khan TM; Benes C; Lifshits E; Ebi H; Rivera VM; Shakespeare WC; Iafrate AJ; Engelman JA; Shaw AT
    Proc Natl Acad Sci U S A; 2011 May; 108(18):7535-40. PubMed ID: 21502504
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma.
    Moore NF; Azarova AM; Bhatnagar N; Ross KN; Drake LE; Frumm S; Liu QS; Christie AL; Sanda T; Chesler L; Kung AL; Gray NS; Stegmaier K; George RE
    Oncotarget; 2014 Sep; 5(18):8737-49. PubMed ID: 25228590
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma.
    Infarinato NR; Park JH; Krytska K; Ryles HT; Sano R; Szigety KM; Li Y; Zou HY; Lee NV; Smeal T; Lemmon MA; Mossé YP
    Cancer Discov; 2016 Jan; 6(1):96-107. PubMed ID: 26554404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors.
    Sasaki T; Koivunen J; Ogino A; Yanagita M; Nikiforow S; Zheng W; Lathan C; Marcoux JP; Du J; Okuda K; Capelletti M; Shimamura T; Ercan D; Stumpfova M; Xiao Y; Weremowicz S; Butaney M; Heon S; Wilner K; Christensen JG; Eck MJ; Wong KK; Lindeman N; Gray NS; Rodig SJ; Jänne PA
    Cancer Res; 2011 Sep; 71(18):6051-60. PubMed ID: 21791641
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ALK mutations conferring differential resistance to structurally diverse ALK inhibitors.
    Heuckmann JM; Hölzel M; Sos ML; Heynck S; Balke-Want H; Koker M; Peifer M; Weiss J; Lovly CM; Grütter C; Rauh D; Pao W; Thomas RK
    Clin Cancer Res; 2011 Dec; 17(23):7394-401. PubMed ID: 21948233
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.
    Butrynski JE; D'Adamo DR; Hornick JL; Dal Cin P; Antonescu CR; Jhanwar SC; Ladanyi M; Capelletti M; Rodig SJ; Ramaiya N; Kwak EL; Clark JW; Wilner KD; Christensen JG; Jänne PA; Maki RG; Demetri GD; Shapiro GI
    N Engl J Med; 2010 Oct; 363(18):1727-33. PubMed ID: 20979472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.
    Doebele RC; Pilling AB; Aisner DL; Kutateladze TG; Le AT; Weickhardt AJ; Kondo KL; Linderman DJ; Heasley LE; Franklin WA; Varella-Garcia M; Camidge DR
    Clin Cancer Res; 2012 Mar; 18(5):1472-82. PubMed ID: 22235099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK.
    Fontana D; Ceccon M; Gambacorti-Passerini C; Mologni L
    Cancer Med; 2015 Jul; 4(7):953-65. PubMed ID: 25727400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Crizotinib-resistant mutants of EML4-ALK identified through an accelerated mutagenesis screen.
    Zhang S; Wang F; Keats J; Zhu X; Ning Y; Wardwell SD; Moran L; Mohemmad QK; Anjum R; Wang Y; Narasimhan NI; Dalgarno D; Shakespeare WC; Miret JJ; Clackson T; Rivera VM
    Chem Biol Drug Des; 2011 Dec; 78(6):999-1005. PubMed ID: 22034911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Co-clinical trials demonstrate superiority of crizotinib to chemotherapy in ALK-rearranged non-small cell lung cancer and predict strategies to overcome resistance.
    Chen Z; Akbay E; Mikse O; Tupper T; Cheng K; Wang Y; Tan X; Altabef A; Woo SA; Chen L; Reibel JB; Janne PA; Sharpless NE; Engelman JA; Shapiro GI; Kung AL; Wong KK
    Clin Cancer Res; 2014 Mar; 20(5):1204-1211. PubMed ID: 24327273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel ALK inhibitor AZD3463 inhibits neuroblastoma growth by overcoming crizotinib resistance and inducing apoptosis.
    Wang Y; Wang L; Guan S; Cao W; Wang H; Chen Z; Zhao Y; Yu Y; Zhang H; Pang JC; Huang SL; Akiyama Y; Yang Y; Sun W; Xu X; Shi Y; Zhang H; Kim ES; Muscal JA; Lu F; Yang J
    Sci Rep; 2016 Jan; 6():19423. PubMed ID: 26786851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Crizotinib-resistant NPM-ALK mutants confer differential sensitivity to unrelated Alk inhibitors.
    Ceccon M; Mologni L; Bisson W; Scapozza L; Gambacorti-Passerini C
    Mol Cancer Res; 2013 Feb; 11(2):122-32. PubMed ID: 23239810
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activating mutations in ALK kinase domain confer resistance to structurally unrelated ALK inhibitors in NPM-ALK-positive anaplastic large-cell lymphoma.
    Zdzalik D; Dymek B; Grygielewicz P; Gunerka P; Bujak A; Lamparska-Przybysz M; Wieczorek M; Dzwonek K
    J Cancer Res Clin Oncol; 2014 Apr; 140(4):589-98. PubMed ID: 24509625
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exceptional response to the ALK and ROS1 inhibitor lorlatinib and subsequent mechanism of resistance in relapsed
    Liu T; Merguerian MD; Rowe SP; Pratilas CA; Chen AR; Ladle BH
    Cold Spring Harb Mol Case Stud; 2021 Aug; 7(4):. PubMed ID: 34210658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody targeting of anaplastic lymphoma kinase induces cytotoxicity of human neuroblastoma.
    Carpenter EL; Haglund EA; Mace EM; Deng D; Martinez D; Wood AC; Chow AK; Weiser DA; Belcastro LT; Winter C; Bresler SC; Vigny M; Mazot P; Asgharzadeh S; Seeger RC; Zhao H; Guo R; Christensen JG; Orange JS; Pawel BR; Lemmon MA; Mossé YP
    Oncogene; 2012 Nov; 31(46):4859-67. PubMed ID: 22266870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A case report of epithelioid inflammatory myofibroblastic sarcoma with RANBP2-ALK fusion gene treated with the ALK inhibitor, crizotinib.
    Kimbara S; Takeda K; Fukushima H; Inoue T; Okada H; Shibata Y; Katsushima U; Tsuya A; Tokunaga S; Daga H; Okuno T; Inoue T
    Jpn J Clin Oncol; 2014 Sep; 44(9):868-71. PubMed ID: 25028698
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The ALK inhibitor PF-06463922 is effective as a single agent in neuroblastoma driven by expression of ALK and MYCN.
    Guan J; Tucker ER; Wan H; Chand D; Danielson LS; Ruuth K; El Wakil A; Witek B; Jamin Y; Umapathy G; Robinson SP; Johnson TW; Smeal T; Martinsson T; Chesler L; Palmer RH; Hallberg B
    Dis Model Mech; 2016 Sep; 9(9):941-52. PubMed ID: 27483357
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.